SMAD6 and prostate cancer: For example, SMAD7 activates the TAK1-p38 MAPK pathway in human prostate cancer cells (Edlund et al., 2003), whereas Smad6 inhibits TGF-β1-induced activation of this pathway (Jung et al., 2013).